Summary
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus
belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab
plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell
carcinoma (ccRCC).
The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to
pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall
survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus
lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in
advanced ccRCC participants.